Clinical impact of major bleeding in patients with venous thrombo -embolism treated with factor Xa inhibitors or vitamin K antagonists an individual patient data meta-analysis

Thrombosis and Haemostasis

Volumn 117, Issue 10, 2017, Pages 1944-1951

  Bleker, Suzanne M ^a   Brekelmans, Marjolein P A ^a   Eerenberg, Elise S ^a   Cohen, Alexander T ^b   Middeldorp, Saskia ^a   Raskob, Gary ^c   Büller, Harry R ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Factor Xa inhibitors; Major bleeding; Venous thromboembolism; Vitamin K antagonists

Indexed keywords

ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; ENOXAPARIN; WARFARIN; ANTICOAGULANT AGENT; VITAMIN K GROUP;

ADULT; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; INTRAOCULAR HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROPERITONEAL HEMORRHAGE; SUBARACHNOID HEMORRHAGE; SUBDURAL HEMATOMA; VAGINA BLEEDING; VENOUS THROMBOEMBOLISM; AGED; ANTAGONISTS AND INHIBITORS; COMPLICATION; DISEASE EXACERBATION; GASTROINTESTINAL DISEASE; ODDS RATIO; VERY ELDERLY; BLOOD; BLOOD TRANSFUSION; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; DISEASE PROGRESSION; FACTOR XA INHIBITORS; FEMALE; GASTROINTESTINAL DISEASES; HEMORRHAGE; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE AGED; ODDS RATIO; VENOUS THROMBOEMBOLISM; VITAMIN K; BLOOD TRANSFUSION; CHI-SQUARE DISTRIBUTION; GASTROINTESTINAL HEMORRHAGE; LOGISTIC MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 85031106589     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH16-12-0946     Document Type: Article

References (20)

1. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799-808.
2. Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
3. Buller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-1297.
4. Büller HR, Décousus H, Grosso M, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406-1415.
5. Robertson L, Kesteven P, McCaslin JE. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism. Cochrane Database Syst Rev 2015; 6: Cd010957.
6. Robertson L, Kesteven P, McCaslin JE. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis. Cochrane Database Syst Rev 2015; 6: Cd010956.
7. Vanassche T, Hirsh J, Eikelboom JW, et al. Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials. Thromb Haemost 2014; 112: 918-923.
8. Beyer-Westendorf J, Michalski F, Tittl L, et al. Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series. Lancet Haematol 2016; 3: e480-e488.
9. Becattini C, Franco L, Beyer-Westendorf J, et al. Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life. Int J Cardiol 2017; 227: 261-266.
10. Brekelmans MP, Scheres LJ, Bleker SM, et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thromb Haemost 2017; Epub ahead of print.
11. Rudd KM, Phillips EL. New oral anticoagulants in the treatment of pulmonary embolism: efficacy, bleeding risk, and monitoring. Thrombosis 2013; 2013: 973710.
12. Gouin B, Blondon M, Jimenez D, et al. Clinical prognosis of non-massive central and non-central pulmonary embolism: a registry-based cohort study. Chest 2016; Epub ahead of print.
13. Eerenberg ES, Middeldorp S, Levi M, et al. Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. J Thromb Haemost 2015; 13: 1590-1596.
14. Brekelmans MP, Bleker SM, Bauersachs R, et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thromb Haemost 2016; 116: 155-161.
15. Bleker SM, Cohen AT, Buller HR, et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial. Thromb Haemost 2016; 116: 1159-1164.
16. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692-694.
17. Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med 2015; 373: 2413-2424.
18. Connolly SJ, Milling TJ, Jr., Eikelboom JW, et al. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. N Engl J Med 2016; 375: 1131-1141.
19. Majeed A, Hwang HG, Connolly SJ, et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 2013; 128: 2325-2332.
20. Berger R, Salhanick SD, Chase M, et al. Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin. Ann Emerg Med 2013; 61: 475-479.